These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 21902648)

  • 1. Cytogenetic and molecular abnormalities in myelodysplastic syndrome.
    Nagoshi H; Horiike S; Kuroda J; Taniwaki M
    Curr Mol Med; 2011 Nov; 11(8):678-85. PubMed ID: 21902648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
    Stahl M; Zeidan AM
    Cancer; 2017 May; 123(10):1703-1713. PubMed ID: 28192601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
    Pellagatti A; Jädersten M; Forsblom AM; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E
    Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11406-11. PubMed ID: 17576924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Myelodysplastic syndromes (MDS)].
    Kizaki M
    Nihon Rinsho; 2014 Jun; 72(6):1079-86. PubMed ID: 25016808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.
    Voutsadakis IA; Cairoli A
    Leuk Lymphoma; 2012 May; 53(5):779-88. PubMed ID: 21955212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More is better: combination therapies for myelodysplastic syndromes.
    Ornstein MC; Mukherjee S; Sekeres MA
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis.
    Matsuoka A; Tochigi A; Kishimoto M; Nakahara T; Kondo T; Tsujioka T; Tasaka T; Tohyama Y; Tohyama K
    Leukemia; 2010 Apr; 24(4):748-55. PubMed ID: 20130600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approach to new therapeutics: investigation by the use of MDS-derived cell lines.
    Tsujioka T; Matsuoka A; Tohyama Y; Tohyama K
    Curr Pharm Des; 2012; 18(22):3204-14. PubMed ID: 22571700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The lower risk MDS patient at risk of rapid progression.
    Mittelman M; Oster HS; Hoffman M; Neumann D
    Leuk Res; 2010 Dec; 34(12):1551-5. PubMed ID: 20573398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic abnormalities and pathophysiology of MDS.
    Hosono N
    Int J Clin Oncol; 2019 Aug; 24(8):885-892. PubMed ID: 31093808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes.
    Olney HJ; Le Beau MM
    Leuk Res; 2007 Apr; 31(4):427-34. PubMed ID: 17161457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelodysplastic syndrome: review of the cytogenetic and molecular data.
    Mhawech P; Saleem A
    Crit Rev Oncol Hematol; 2001 Dec; 40(3):229-38. PubMed ID: 11738946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelodysplastic syndromes: Contemporary review and how we treat.
    Gangat N; Patnaik MM; Tefferi A
    Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of lenalidomide in the treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for biology- and molecular-based treatment of myelodysplastic syndromes.
    Lindberg EH
    Curr Drug Targets; 2005 Sep; 6(6):713-25. PubMed ID: 16178803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
    Zeidan AM; Al Ali NH; Padron E; Lancet J; List A; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):705-10. PubMed ID: 26440749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide in myelodysplastic syndrome and multiple myeloma.
    Shah SR; Tran TM
    Drugs; 2007; 67(13):1869-81. PubMed ID: 17722955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.